# First-in-Human Single Ascending Dose of GLPG0492

> **NCT01130818** · PHASE1 · COMPLETED · sponsor: **Lakefront Biotherapeutics NV** · enrollment: 28 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** GLPG0492
- **DRUG:** placebo
- **DRUG:** GLPG0492
- **DRUG:** GLPG0492

## Key facts

- **NCT ID:** NCT01130818
- **Lead sponsor:** Lakefront Biotherapeutics NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2010-08
- **Final completion:** 2010-09
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2024-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01130818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01130818, "First-in-Human Single Ascending Dose of GLPG0492". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01130818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*